Results for omalizumab translation from Danish to English

omalizumab.
omalizumab.

aktivt stof: omalizumab.
the active substance is omalizumab.

-det aktive stof er omalizumab.
-the active substance is omalizumab.

uge omalizumab eller placebo administreret
week omalizumab or placebo administered

1 hætteglas indeholder 150 mg omalizumab.
one vial contains 150 mg omalizumab.

omalizumab-studie 1 og 3 poolet
omalizumab studies 1 and 3 pooled

hvert hætteglas indeholder 150 mg omalizumab.
each vial delivers 150 mg of omalizumab.

der er ikke udført formelle karcinogenicitetsundersøgelser med omalizumab.
formal carcinogenicity studies have not been conducted with omalizumab.

1 ml injektionsvæske, opløsning indeholder 150 mg omalizumab.
1 ml solution for injection contains 150 mg omalizumab.

hvert hætteglas indeholder 75 eller 150 mg omalizumab.
each vial and syringe contains 75 or 150 mg of omalizumab.

xolair 150 mg injektionsvæske, opløsning omalizumab s. c. anvendelse
xolair 150 mg solution for injection omalizumab sc use

xolair 150 mg pulver og solvens til injektionsvæske, opløsning omalizumab
xolair 150 mg powder and solvent for solution for injection omalizumab

xolair 75 mg pulver til injektionsvæske, opløsning omalizumab subkutan anvendelse
xolair 75 mg powder for solution for injection omalizumab subcutaneous use

xolair 75 mg injektionsvæske, opløsning xolair 150 mg injektionsvæske, opløsning omalizumab
xolair 75 mg solution for injection xolair 150 mg solution for injection omalizumab

omalizumab reducerede hyppigheden af astmaeksacerbationer med 19 % (p = 0,153).
omalizumab reduced the rate of asthma exacerbations by 19% (p = 0.153).

anafylaktisk reaktion, andre alvorlige allergiske tilstande, udvikling af anti-omalizumab-antistof
anaphylactic reaction, other serious allergic conditions, anti- omalizumab antibody development

omalizumabs farmakokinetik er lineær ved doser over 0,5 mg/kg.
the pharmacokinetics of omalizumab are linear at doses greater than 0.5 mg/kg.